Summit Therapeutics PLC (NASDAQ: SMMT) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Summit Therapeutics PLC to similar businesses based on the strength of its earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Summit Therapeutics PLC and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics PLC 0 0 4 0 3.00
Summit Therapeutics PLC Competitors 1419 4561 12470 314 2.62

Summit Therapeutics PLC currently has a consensus target price of $27.75, indicating a potential upside of 122.18%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 29.03%. Given Summit Therapeutics PLC’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Summit Therapeutics PLC is more favorable than its competitors.

Institutional & Insider Ownership

21.8% of Summit Therapeutics PLC shares are held by institutional investors. Comparatively, 51.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Summit Therapeutics PLC and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Summit Therapeutics PLC -12.44% -29,334.40% -7.61%
Summit Therapeutics PLC Competitors -5,564.71% -392.13% -42.65%

Valuation & Earnings

This table compares Summit Therapeutics PLC and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Summit Therapeutics PLC $30.33 million -$9.46 million -35.69
Summit Therapeutics PLC Competitors $473.33 million $171.79 million -7.09

Summit Therapeutics PLC’s competitors have higher revenue and earnings than Summit Therapeutics PLC. Summit Therapeutics PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Summit Therapeutics PLC has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Summit Therapeutics PLC’s competitors have a beta of 6.61, indicating that their average share price is 561% more volatile than the S&P 500.

Summary

Summit Therapeutics PLC competitors beat Summit Therapeutics PLC on 7 of the 12 factors compared.

About Summit Therapeutics PLC

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.